ENTITY
BeOne

BeOne (ONC US)

166
Analysis
Health Care • China
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
•14 Mar 2022 08:59

China ADRs & HFCAA: Pace of Homecoming Listings Should Pick Up & Implications

The SEC naming 5 companies under the HFCAA put China ADRs under pressure last week. The news that the CAC had nixed DIDI's HK listing plans added...

Logo
786 Views
Share
•14 Mar 2022 08:57

Jiangsu Hengrui Medicine (600276.CH) - Here’s when Hengrui May Recover

We analyzed the possible future development trajectory of Hengrui's performance. Due to its  "DNA"  and development mode, after recovering,...

Logo
414 Views
Share
•13 Mar 2022 09:03

China Healthcare Weekly (Mar.11) - 2022 Government Work Report, Expensive Monkeys, Technology Patent

We listed the key points about healthcare industry in 2022 government work report. Companies should notice the skyrocketed experimental monkey...

Logo
333 Views
Share
•12 Mar 2022 18:13

GEM Weekly (11 Mar 2022): Chinese Macro Data; Samsung Electronics, Swiggy, Naver, Yum China

The Global Emerging Markets weekly provides a summary of the key news and related developments impacting the largest countries and constituents of...

Share
bearish•Alibaba
•11 Mar 2022 13:38

China ADRs Delisting - SEC Sets the Clock Ticking and Sends China ADRs Tripping

On 8th Mar 2022, Securities Exchange Commission (SEC) added five China ADR names to its provisional list of issuers under the Holding Foreign...

Logo
983 Views
Share
x